Skip to main content
Opthea Ltd logo

Opthea Ltd — Investor Relations & Filings

Ticker · OPT ISIN · US68386J2087 LEI · 549300Q5FMFDLP46SF83 ASX Manufacturing
Open in API
Filings indexed 1,390 across all filing types
Latest filing 2014-11-24 Regulatory Filings
Country AU Australia
Listing ASX OPT

About Opthea Ltd

https://opthea.com/

Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's lead product candidate, sozinibercept, is a first-in-class biologic 'trap' inhibitor targeting Vascular Endothelial Growth Factors C and D (VEGF-C and VEGF-D). Sozinibercept is being developed for administration in combination with standard-of-care anti-VEGF-A therapies. This dual-pathway inhibition aims to deliver superior visual outcomes by more comprehensively blocking the mechanisms that contribute to disease progression, addressing the limitations of current treatments that only target VEGF-A. The therapy is being evaluated in late-stage pivotal clinical trials for wet AMD.

Recent filings

Filing Released Lang Actions
Becoming a substantial holder 60 pages 8.7MB
Regulatory Filings
2014-11-24 English
Change in substantial holding 4 pages 138.4KB
Regulatory Filings
2014-11-24 English
Completion of Placement and Appendix 3B 17 pages 202.5KB
Capital/Financing Update Classification · 100% confidence The document is a detailed announcement regarding the placement of new shares and options following shareholder approval at an Annual General Meeting. It includes an Appendix 3B form, which is a standard ASX form used for new issue announcements, application for quotation of additional securities, and agreements related to capital raising. The document provides extensive details about the securities issued, their terms, issue price, purpose, and compliance with ASX rules. It is not a full financial report, earnings release, or management discussion, but rather a formal announcement of a capital raising event and related securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is not merely a brief announcement or a report publication notice, but a substantive filing about capital raising.
2014-11-24 English
Change of Director's Interest Notice 2 pages 77.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's acquisition of shares and options, including dates, quantities, and consideration. The content is focused on reporting a change in a director's personal shareholding interests. There is no financial performance data, management discussion, or report publication. The document is a regulatory disclosure of insider trading by a director, which fits the definition of 'Director's Dealing' filings.
2014-11-19 English
Change of Director's Interest Notice 2 pages 80.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of shares held before and after the change, nature of the interest, and transaction details. This matches the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document length is 4032 characters, which is consistent with a detailed notice rather than a brief announcement or a full report. Therefore, the correct classification is Director's Dealing (DIRS).
2014-11-19 English
Change of Director's Interest Notice 2 pages 80.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of shares before and after the change, nature of the interest, and dates. This is a formal notification of a director's personal share transactions. The document length is 4011 characters, which is typical for such notices. There is no financial performance data, earnings information, or management discussion. The content matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives (insider trades).
2014-11-18 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.